AzurRx BioPharma, Inc. - FORM 10-Q - EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - November 13, 2017

Attached files

file filename
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - AzurRx BioPharma, Inc.ex31-1.htm
EX-32.2 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - AzurRx BioPharma, Inc.ex32-2.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - AzurRx BioPharma, Inc.ex31-2.htm
EX-10.1 - MODIFICATION TO 12% SENIOR SECURED ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE - AzurRx BioPharma, Inc.ex10-1.htm
10-Q - QUARTERLY REPORT - AzurRx BioPharma, Inc.azrx10q_sep302017.htm
 
Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
 In connection with the Quarterly Report of AzurRx BioPharma, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Johan M. (Thijs) Spoor, the President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:
 
 (1)  The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 (2)  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
November 13, 2017
 
 
/s/ Johan M. (Thijs) Spoor
 
Johan M. (Thijs) Spoor
President and Chief Executive Officer
(Principal Executive Officer)
 
 
 

AzurRx BioPharma, Inc. Reports